volagidemab 12-week treatment in 18–65 years T1D patients (volagidemab 35 mg: 2 patients, volagidemab 70 mg: 2 patients, placebo: 27 patients) failed to reduce the daily insulin use but showed a significant reduction in HbA1c and tolerable safety profile. Here, INS is linked to type 1 diabetes mellitus.